Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.42 |
| ▸ | PI4KA | P42356 | 5/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057395 | 1.00 | AHCY (0.48) | AHCYADORA2ATP53PDE8BADORA1 | |
| SCHEMBL21057392 | 1.00 | AHCY (0.48) | AHCYADORA2ATP53PDE8BADORA1 | |
| SCHEMBL24686947 | 0.92 | ADORA2A (0.54) | AHCYADORA2APDE8BADORA1PI4KB | |
| SCHEMBL21138851 | 0.86 | ADORA2A (0.56) | AHCYADORA2ATP53PDE8BADORA1 | |
| SCHEMBL21138165 | 0.85 | AHCY (0.51) | AHCYADORA2ATP53PDE8BADORA1 | |
| SCHEMBL21057329 | 0.85 | ADORA2A (0.57) | AHCYADORA2APDE8BADORA1PI4KB | |
| SCHEMBL21058221 | 0.85 | ADORA2A (0.57) | AHCYADORA2APDE8BADORA1PI4KB | |
| SCHEMBL21138474 | 0.85 | AHCY (0.48) | AHCYADORA2APDE8BADORA1PI4KB | |
| Hydrochloric Acid SCHEMBL21057461 | 0.84 | ADORA2A (0.56) | AHCYADORA2APDE8BADORA1PI4KB | |
| SCHEMBL21057264 | 0.83 | ADORA2A (0.48) | AHCYADORA2ATP53PDE8BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | claimed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | AHCY 1944/4885ADORA2A 2108/4885TP53 2963/4885 |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | AHCY 1959/4885ADORA2A 1642/4885TP53 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.